RE:RE:Guidance.....Correct - without guidlance funds can not buy this stock (regulations prohibit purchase), and institutions won't touch it. The share price will not be able to go upwards with retail purchases alone. This is unfortunate for any retail long on this stock.
GenericAdvocate wrote: If they can't offer guidance, then institutions will not ... and many CAN NOT.. buy ....
That is like saying in December, well we can't offer guidance because we don't know if Brexit is going through...
The end result is, that the investment community has NO confidence that they can service their debt without guidance.
So the share price will continue to slide. Insiders are probably short their own stock
happyretirement wrote: How could anyone expect Concordia which has a majority of their drugs sold in the UK which should finalize the Health Service Medical Supplies (Costs) Bill in the coming months and has already had many of their drugs changed from both "A & C" to "M" which puts pricing control into the hands of the DoH, no company in their right minds would make any type of estimate with the current outlook for 2017 from the UK Government.....CMA issues will be something that could be pushed out till next year and beyond as shown from previous cases such as Pfizer and others....
JMO